Understanding Treatment
Response Heterogeneity
Intra-patient heterogeneity is nearly universal in cancer.1. Having as few at 9% of lesions not responding to therapy can result in significantly worse outcomes.2,3
SUVhetero is an imaging metric of intra-patient heterogeneity. Change in SUVhetero was the most significant predictor of time to PSA progression (hazard ratio [HR], 3.88; 95% CI, 1.24 to 12.1) and time to treatment discontinuation (HR, 4.21; 95% CI, 1.28 to 13.8) in a study of men with progressive metastatic castration-resistant prostate cancer (mCRPC).3

1. Meacham et al, Nature, 2013; 2. Harmon et al., J Clin Oncol 2017, including unpublished supplemental data analysis; 3. Kyriakopoulos et al, J Clin Oncol 2020.
TRAQinform IQ Technology
TRAQinform IQ is a software medical device that provides novel information about quantification of change in regions of interest over time. Oncologists use this technology to more precisely adjust therapies and optimize clinical outcomes.
![]() TRAQinform IQ uses serial radiographic images (e.g., PET, CT) |
![]() |
![]() Images are uploaded via the cloud to AIQ solutions (HIPAA compliant) |
![]() |
![]() Software that provides novel, quantitative and spatial information about each region of interest |
![]() |
![]() A comprehensive report is generated and delivered to the oncologist |
![]() |
![]() Oncologists can use the information to tailor treatment regimens and optimize outcomes |
